Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Aren’t Crazy About Nektar Therapeutics (NKTR) Anymore

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn’t mean that they don’t have occasional colossal losses; they do (like Ackman’s recent Valeant losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let’s examine the smart money sentiment towards Nektar Therapeutics (NASDAQ:NKTR).

Is Nektar Therapeutics (NASDAQ:NKTR) going to take off soon? Prominent investors are becoming less confident. The number of bullish hedge fund bets shrunk by 10 recently. Nektar Therapeutics (NASDAQ:NKTR) was in 11 hedge funds’ portfolios at the end of the third quarter of 2015. There were 21 hedge funds in our database with Nektar Therapeutics (NASDAQ:NKTR) positions at the end of the previous quarter. At the end of this article, we will also compare Nektar Therapeutics (NASDAQ:NKTR) to other stocks, including LegacyTexas Financial Group Inc (NASDAQ:LTXB), Synchronoss Technologies, Inc. (NASDAQ:SNCR), and Greatbatch Inc (NYSE:GB) to get a better sense of its popularity.

Follow Nektar Therapeutics (NASDAQ:NKTR)
Trade (NASDAQ:NKTR) Now!

According to most shareholders, hedge funds are perceived as underperforming, outdated investment vehicles of yesteryear. While there are greater than 8000 funds trading at the moment, Our experts hone in on the elite of this group, approximately 700 funds. These investment experts control bulk of all hedge funds’ total capital, and by watching their best investments, Insider Monkey has identified various investment strategies that have historically exceeded Mr. Market. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points per year for a decade in their back tests.

Now, we’re going to take a peek at the key action surrounding Nektar Therapeutics (NASDAQ:NKTR).

How are hedge funds trading Nektar Therapeutics (NASDAQ:NKTR)?

Heading into Q4, a total of 11 of the hedge funds tracked by Insider Monkey were long this stock, a drop of 48% from the previous quarter. With hedgies’ capital changing hands, there exists a select group of notable hedge fund managers who were upping their stakes substantially (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Israel Englander’s Millennium Management has the most valuable position in Nektar Therapeutics (NASDAQ:NKTR), worth close to $44.2 million, comprising 0.1% of its total 13F portfolio. The second largest stake is held by Stephen DuBois of Camber Capital Management, with a $24.7 million position; 2.1% of its 13F portfolio is allocated to the company. Some other peers that hold long positions consist of Paul Sinclair’s Blue Jay Capital Management, Bihua Chen’s Cormorant Asset Management, and Jonathan Lourie and Stuart Fiertz’s Cheyne Capital.

Since Nektar Therapeutics (NASDAQ:NKTR) has faced a declining sentiment from the smart money, logic holds that there lies a certain “tier” of fund managers who sold off their full holdings heading into Q4. At the top of the heap, Joel Greenblatt’s Gotham Asset Management cut the biggest position of all the hedgies tracked by Insider Monkey, comprising about $17.1 million in stock. D E Shaw also cut its stock, about $6.6 million worth of shares. These bearish behaviors are interesting, as total hedge fund interest dropped by 10 funds heading into Q4.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Nektar Therapeutics (NASDAQ:NKTR) but similarly valued. These stocks are LegacyTexas Financial Group Inc (NASDAQ:LTXB), Synchronoss Technologies, Inc. (NASDAQ:SNCR), Greatbatch Inc (NYSE:GB), and Concordia Healthcare Corp (NASDAQ:CXRX). This group of stocks’ market caps matches Nektar Therapeutics (NASDAQ:NKTR)’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
LTXB 10 73448 -1
SNCR 21 97209 0
GB 19 136317 0
CXRX 17 227015 4

As you can see, these stocks had an average of 17 hedge funds with bullish positions and the average amount invested in these stocks was $133 million. That figure was $92 million in Nektar Therapeutics (NASDAQ:NKTR)’s case. Synchronoss Technologies, Inc. (NASDAQ:SNCR) is the most popular stock in this table. On the other hand, LegacyTexas Financial Group Inc (NASDAQ:LTXB) is the least popular one with only 10 bullish hedge fund positions. Nektar Therapeutics (NASDAQ:NKTR) is not the least popular stock in this group, but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard, Synchronoss Technologies, Inc. (NASDAQ:SNCR) might be a better candidate to consider a long position.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!